Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
This notice reports that shareholder Michael Y. Chi plans to sell 13,750 Class A shares of the issuer on or about 12/17/2025 through Fidelity Brokerage Services on the NYSE. The shares have an aggregate market value of $504,762.50, while total Class A shares outstanding are 219,270,891.
The securities to be sold were acquired from the issuer on 12/15/2025 through restricted stock vesting as compensation, with the same date listed for acquisition and payment. The filing also lists several prior Class A share sales by Michael Y. Chi over the past three months, including 13,749 shares sold on 09/17/2025 for gross proceeds of $694,324.50.
HIMS stockholder Irene Becklund has filed a notice to sell 8,411 Class A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $308,767.81. The notice also lists 219,270,891 Class A shares outstanding.
The shares to be sold were acquired on 12/15/2025 via restricted stock vesting from the issuer as compensation, with payment also dated that day. Over the prior three months, Becklund sold 8,410 Class A shares on 09/17/2025 for gross proceeds of $424,705.00.
A holder of HIMS Class A stock has filed a Rule 144 notice to sell 7054 shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 258952.34 and an approximate sale date of 12/17/2025. These Class A shares were acquired from the issuer on 12/15/2025 via restricted stock vesting as compensation, in the same amount of 7054 shares. The notice lists 219270891 Class A shares outstanding, providing context for the planned sale.
Hims & Hers Health, Inc. reported an insider equity transaction by Chief Legal Officer Soleil Boughton. On December 15, 2025, restricted stock units (RSUs) converted into 41,421 shares of Class A common stock. To cover tax withholding obligations from this vesting, the company withheld 22,817 Class A shares at $36.25 per share, after which Boughton directly owned 171,829 Class A shares.
The reported RSUs each represent a contingent right to receive one share of Class A common stock. Several RSU grants are subject to service-based vesting over four years, in substantially equal quarterly installments on Company Quarterly Vesting Dates, with first vesting dates beginning on June 15, 2022, June 15, 2023, June 15, 2024, and June 15, 2025.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison Carroll reported equity compensation activity dated December 15, 2025. Restricted stock units (RSUs) converted into 16,521 shares of Class A common stock (transaction code M), increasing his direct holdings to 186,461 shares before tax withholding.
The issuer then withheld 6,500 shares at $36.25 per share (transaction code F) to satisfy tax withholding obligations tied to the RSU vesting, leaving Carroll with 179,961 directly held shares. The RSUs vest over four-year service periods: one grant vests 25% on December 15, 2023 with the remainder in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, and additional grants vest quarterly on these same Company Quarterly Vesting Dates starting June 15, 2024 and June 15, 2025.
Hims & Hers Health, Inc. reported insider equity activity by its chief executive officer, who is also a director and 10% owner, on December 15, 2025. The filing shows the acquisition of 164,369 shares of Class A Common Stock through the settlement of restricted stock units.
On the same date, 90,660 shares of Class A Common Stock were disposed of at $36.25 per share, as the issuer withheld these shares to cover tax withholding obligations related to the RSU vesting. Following these transactions, the reporting person held 878,732 Class A shares directly, in addition to substantial indirect holdings through multiple family trusts.
The RSU awards each convert into one share of Class A Common Stock and are subject to four-year, service-based vesting in substantially equal quarterly installments on Company Quarterly Vesting Dates. Depending on the grant, these quarterly vesting schedules began on June 15, 2022, June 15, 2023, June 15, 2024 and June 15, 2025.
Hims & Hers Health, Inc. officer Irene Becklund reported equity transactions dated 12/15/2025. She acquired 17,986 shares of Class A Common Stock through the vesting and settlement of restricted stock units, and 8,867 shares of Class A Common Stock were withheld by the issuer at $36.25 per share to cover tax withholding obligations. After these transactions she directly owned 10,537 shares of Class A Common Stock.
The report also lists multiple restricted stock unit (RSU) awards, each representing a contingent right to receive one share of Class A Common Stock for each RSU. These RSUs are subject to service-based vesting over four-year periods, generally in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, with initial vesting dates beginning on various company quarterly vesting dates from 06/15/2022 through 06/15/2025.
Hims & Hers Health reported insider equity activity by its Chief Financial Officer, Oluyemi Okupe. On December 15, 2025, restricted stock units (RSUs) vested and were settled into 105,201 shares of Class A common stock. The issuer withheld 58,010 shares at $36.25 per share to cover tax withholding obligations from this vesting, leaving Okupe with 117,423 shares held directly and 7,853 shares held indirectly through a separate property trust.
The RSUs each represent a contingent right to receive one share of Class A common stock. Several RSU grants are subject to four-year service-based vesting schedules on quarterly dates of March 15, June 15, September 15 and December 15, with different grants beginning to vest on March 15, 2023, June 15, 2023, June 15, 2024 and June 15, 2025.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported equity compensation activity involving the company’s Class A common stock on December 15, 2025. He acquired 72,106 shares through the vesting and settlement of previously granted restricted stock units, increasing his direct holdings before tax withholding.
To cover related tax obligations, 39,870 shares were withheld by the company at a price of $36.25 per share. After these transactions, Chi directly beneficially owned 318,911 shares of Class A common stock. Multiple restricted stock unit awards continue to vest on a quarterly schedule over four-year service-based periods, with different grants beginning vesting on various Company Quarterly Vesting Dates from June 15, 2022 through June 15, 2025.
Hims & Hers Health, Inc. reported an insider equity transaction by director and Chief Policy Officer Deborah M Autor. On December 15, 2025, 7,054 restricted stock units (RSUs) were converted into the same number of Class A common shares, increasing her directly held stake to 13,229 shares.
The RSUs carry a service-based vesting schedule over three years. One third vests on December 15, 2025, another third on December 15, 2026, and the final third on December 15, 2027. After this transaction, Autor continues to hold 14,110 RSUs, each representing the right to receive one Class A common share at no cash exercise price.